Impact of AI on the Drug M&A Market

Xiao Huang:DOORM, what impact has AI had on the drug M&A market? What specific effects can we observe?

DOORM:AI has had a significant impact on the drug M&A market. Firstly, the application of AI technology has led to a large number of new drugs entering the industrial stage, even if they have not yet been marketed but have entered clinical trials. Data shows that the number of drug-related mergers and acquisitions is growing at an annual rate of 27.3%, with a global M&A scale of about $100 billion, of which AI-related drugs account for about 15%. This indicates that the application of AI in drug development is driving rapid growth in the entire industry.